New U.S. body to evaluate antimicrobial products

An analytical decision-tree model framework that can be used to assess the impacts of different possible market incentives on the private and social returns to product development of new antibacterial products (in contrast to those already under development).

It is hoped that the model can be used to “nudge” pharmaceutical companies into developing a new generation of life-saving antimicrobial products.